United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2012_register executive 2012-10-29 article Notices D09002ee1c7fc402b D09002ee1c7fc40a7 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive evaluation option license to practice the inventions embodied in PCT Patent Application No. PCT/US2009/054478, U.S. Patent Application No. 13/059,335 and foreign equivalents thereof entitled "Chemopreventive of Head and Neck Squamous Cell Carcinoma" (HHS Ref. No. E-302-2008/0) and PCT Patent Application No. PCT/IL2010/000694, U.S. Patent Application No. 13/391,756 and foreign equivalents thereof entitled "Prevention and Treatment of Oral and Lips Diseases Using Sirolimus and Derivatives Sustained Release Delivery Systems for Local Application to the Oral Cavity" (HHS Ref. No. E-282-2009/0) to Rapamycin Holdings, Inc., which is located in San Antonio, TX. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive evaluation option license territory may be worldwide and the field of use may be limited to use of the Licensed Patent Rights for the prevention and treatment of head and neck cancers. Upon the expiration or termination of the exclusive evaluation option license, Rapamycin Holdings, Inc. will have the exclusive right to execute an exclusive commercialization license which will supersede and replace the exclusive evaluation option license with no greater field of use and territory than granted in the exclusive evaluation option license. 77 FR 65699 https://www.govinfo.gov/app/details/FR-2012-10-30/2012-26606 2012-26606 fr30oc12-68 4140-01-P https://www.govinfo.gov/app/details/FR-2012-10-30/2012-26606 https://www.govinfo.gov/content/pkg/FR-2012-10-30/html/2012-26606.htm https://www.govinfo.gov/content/pkg/FR-2012-10-30/pdf/2012-26606.pdf 2 p. 65699 65700 77 FR 65699 Prospective Grant of Exclusive License: Development of Chemopreventive Treatments for Head and Neck Squamous Cell Carcinoma; Federal Register Vol. 77, Issue NOTICE 2012-26606 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2012-11-14 4140-01-P 2012-26606 Notice.

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive evaluation option license to practice the inventions embodied in PCT Patent Application No. PCT/US2009/054478, U.S. Patent Application No. 13/059,335 and foreign equivalents thereof entitled "Chemopreventive of Head and Neck Squamous Cell Carcinoma" (HHS Ref. No. E-302-2008/0) and PCT Patent Application No. PCT/IL2010/000694, U.S. Patent Application No. 13/391,756 and foreign equivalents thereof entitled "Prevention and Treatment of Oral and Lips Diseases Using Sirolimus and Derivatives Sustained Release Delivery Systems for Local Application to the Oral Cavity" (HHS Ref. No. E-282-2009/0) to Rapamycin Holdings, Inc., which is located in San Antonio, TX. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive evaluation option license territory may be worldwide and the field of use may be limited to use of the Licensed Patent Rights for the prevention and treatment of head and neck cancers. Upon the expiration or termination of the exclusive evaluation option license, Rapamycin Holdings, Inc. will have the exclusive right to execute an exclusive commercialization license which will supersede and replace the exclusive evaluation option license with no greater field of use and territory than granted in the exclusive evaluation option license.

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 14, 2012 will be considered. Prospective Grants of Exclusive Licenses: Development of Chemopreventive Treatments for Head and Neck Squamous Cell Carcinoma , hastingw@mail.nih.gov Vol. 77, no. 210 Office of the Federal Register, National Archives and Records Administration 2012-10-30 continuing daily deposited born digital 172 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2012-10-30 P0b002ee18372bc2f 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr30oc12 https://www.govinfo.gov/app/details/FR-2012-10-30 https://www.govinfo.gov/content/pkg/FR-2012-10-30/pdf/FR-2012-10-30.pdf https://www.govinfo.gov/content/pkg/FR-2012-10-30/xml/FR-2012-10-30.xml fdlp 65611 65771 DGPO 2012-10-29 2024-06-03 FR-2012-10-30 machine generated eng FR FR-2012-10-30 77 210